

This is the peer reviewed version of the following article:

Early progression as a predictor of survival in marginal zone lymphomas: An analysis from the FIL-NF10 study / Luminari, Stefano; Merli, Michele; Rattotti, Sara; Tarantino, Vittoria; Marcheselli, Luigi; Cavallo, Federica; Varettoni, Marzia; Bianchi, Benedetta; Merli, Francesco; Tedeschi, Alessandra; Cabras, Giuseppina; Re, Francesca; Visco, Carlo; Delamain Marcia, Torresan; Cencini, Emanuele; Spina, Michele; Ferrero, Simone; Ferrari, Angela; Deodato, Marina; Mannina, Donato; Annibali, Ombretta; Rago, Angela; Orsucci, Lorella; Defrancesco, Irene; Frigeni, Marco; Cesaretti, Marina; Arcaini, Luca. - In: BLOOD. - ISSN 1528-0020. - 134:10(2019), pp. 798-801. [10.1182/blood.2019001088]

Terms of use:

The terms and conditions for the reuse of this version of the manuscript are specified in the publishing policy. For all terms of use and more information see the publisher's website.

18/10/2024 14:27

18/10/2024 14:27



American Society of Hematology
2021 L Street NW, Suite 900,
Washington, DC 20036
Phone: 202-776-0544 | Fax 202-776-0545
editorial@hematology.org

Early Progression As a Predictor of Survival in Marginal Zone Lymphomas: An Analysis from the FIL-NF10 Study

Tracking no: BLD-2019-001088R3

Stefano Luminari (Hematology, AUSL IRCCS di Reggio Emilia, Italy) Michele Merli (Division of Hematology, University Hospital "Ospedale di Circolo e Fondazione Macchi"; - ASST Sette Laghi, University of Insubria, Varese, Italy, Italy) Sara Rattotti (Division of Hematology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy, Italy) Vittoria Tarantino (PhD Program in Clinical and Experimental Medicine, University of Modena and Reggio Emilia, Modena, Italy; Lymphoma unit, Department of Onco-hematology, IRCCS San Raffaele Scientific Institute, Milano, Italy, Italy) Luigi Marcheselli (University of Modena and Reggio Emilia, FIL trial Office, Italy) Federica Cavallo (Department of Molecular Biotechnologies and Health Sciences, Hematology Division, University of Torino, Turin, Italy; Division of Hematology 1, AOU "Città' della Salute e della Scienza di Torino"; Torino, Italy, Italy) Marzia Varettoni (Fondazione IRCCS Policlinico San Matteo, Italy) Benedetta Bianchi (University Hospital "Ospedale di Circolo e Fondazione Macchi" - ASST Sette Laghi, University of Insubria, Varese, Italy, Italy) Francesco Merli (AUSL-IRCCS di Reggio Emilia, Italy) Alessandra Tedeschi (Department of Hematology, Niguarda Cancer Center, Niguarda Hospital, Milan, Italy, Italy) Giuseppina Cabras (Division of Hematology, Ospedale Oncologico Armando Businco, Cagliari, Italy, Italy) Francesca Re (AOU di Parma, Italy) Carlo Visco (University of Verona, Italy) Marcia Delamain (Center of Hematology and Hemotherapy, Department of Internal Medicine, Faculty of Medicine, State University of Campinas, Campinas-SP, Brazil, Brazil) Emanuele Cencini (Azienda Ospedaliera Universitaria Senese & University of Siena, Italy, Italy) Michele Spina (National Cancer Institute - Aviano, Italy) Simone Ferrero (Department of Molecular Biotechnologies and Health Sciences, Hematology Division, University of Torino, Turin, Italy; Division of Hematology 1, AOU "Città' della Salute e della Scienza di Torino"; Torino, Italy, Italy) Angela Ferrari (AUSL IRCCS di Reggio Emilia, Italy) Marina Deodato (Department of Hematology, Niguarda Cancer Center, Niguarda Hospital, Milan, Italy, Italy) Donato Mannina (Department of Hematology, Azienda Ospedaliera Papardo, Messina, Italy, Italy) Ombretta Annibali (Unit of Hematology, Stem Cell Transplantation, Transfusion Medicine and Cellular Therapy, University "Campus Bio-Medico"; Rome, Italy, Italy) Angela Rago (Department of Cellular Biotechnology & Hematology, University "La Sapienza"; - Rome, Italy) Lorella Orsucci (AOU "Città della Salute e della Scienza di Torino", Torino, Italy, Italy) Irene Defrancesco (Department of Hematology Oncology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy) Marco Frigeni (Department of Molecular Medicine, University of Pavia, Pavia Italy, Italy) Marina Cesaretti (Fondazione Italiana Linfomi, Italy) Luca Arcaini (Division of Hematology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; Department of Molecular Medicine, University of Pavia, Pavia Italy, Italy)

Abstract:

Marginal zone Lymphomas (MZL) are indolent B cell non Hodgkin Lymphoma (INFL) and have a heterogeneous clinical behavior. Recently time to progression shorter than 24 months (POD24) was identified to stratify overall survival (OS) in follicular NHL and in INFL. Here we examined the ability of POD24 to predict subsequent OS in a large, international cohort of MZL as part of the NF10 prospective international registry (NCT02904577) headed by Fondazione Italiana Linfomi (FIL). POD24 was calculated only for MZL patients requiring immediate therapy and was defined as experiencing lymphoma progression within 24 months from diagnosis. Among the 1,325 patients enrolled in the NF10 study we identified 321 pts with MZL for whom immediate therapy was planned right after lymphoma diagnosis. Overall POD24 was confirmed in 59 patients (18%). Three-year OS for patients with POD24 was 53% with a HR of 19.5 (95%CI 8.4-45) compared with patients without POD24 (3 yr OS 95%). Association of POD24 with OS was confirmed for the subgroup of splenic and extranodal MZL. Assessment of POD24 stratifies subsequent outcome in MZL and identifies high risk population.

Conflict of interest: COI declared - see note

COI notes: SL holds a consultancy/advisory role from Roche, Celgene, Sandoz, Gilead and Teva. FC holds advisory role from Takeda and Janssen Cilag. MV holds advisory role from Janssen Cilag and Roche; travel expenses from Janssen Cilag, Abbvie and Gilead. FM holds an advisory role from Roche, Celgene and Sandoz; honoraria from Roche, Gilead, Mundipharma, Janssen and Takeda; travel expenses from Takeda and Celgene; research funding from Roche. DM holds advisory role from Janssen Cilag and Abbvie. OA hold advisory role from Celgene, Takeda, Janssen Cilag, Roche, Servier and Amgen; sponsorships from Gilead, Janssen Cilag, Servier, Celgene Takeda and Amgen. LA reports consulting or advisory roles for Bayer, Celgene, Gilead Sciences, Roche, Sandoz, Janssen-Cilag, VERASTEM and research funding from Gilead Sciences and participation in a speakers bureau for Celgene. All other authors have nothing to declare.

Preprint server: No;

Author contributions and disclosures: SL and LA designed research, analyzed an interpreted data. LM performed statistical analysis, analyzed an interpreted data. All authors performed research, collected data, wrote and approved manuscript

Non-author contributions and disclosures: No;

Agreement to Share Publication-Related Data and Data Sharing Statement: N/A

Clinical trial registration information (if any): ClinicalTrials.gov Identifier: NCT02904577

Early Progression As a Predictor of Survival in Marginal Zone Lymphomas: An Analysis from the FIL-NF10 Study

Stefano Luminari^{1,2}, Michele Merli³, Sara Rattotti⁴, Vittoria Tarantino^{5,6}, Luigi Marcheselli⁷, Federica Cavallo^{8,9}, Marzia Varettoni⁴, Benedetta Bianchi³, Francesco Merli¹, Alessandra Tedeschi¹⁰, Giuseppina Cabras¹¹, Francesca Re¹², Carlo Visco¹³, Marcia Torresan Delamain¹⁴, Emanuele Cencini¹⁵, Michele Spina¹⁶, Simone Ferrero^{8,9}, Angela Ferrari¹, Marina Deodato¹⁰, Donato Mannina¹⁷, Ombretta Annibali¹⁸, Angela Rago¹⁹, Lorella Orsucci²⁰, Irene Defrancesco⁴, Marco Frigeni²¹, Marina Cesaretti,⁷ Luca Arcaini^{4,21}

¹Division of Hematology, Azienda USL IRCCS Reggio Emilia, Italy

²Surgical, Medical and Dental Department of Morphological Sciences related to Transplant, Oncology and Regenerative Medicine Department, University of Modena and Reggio Emilia, Italy

³Division of Hematology, University Hospital "Ospedale di Circolo e Fondazione Macchi" - ASST Sette Laghi, University of Insubria, Varese, Italy

⁴Division of Hematology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy

⁵PhD Program in Clinical and Experimental Medicina, University of Modena and Reggio Emilia, Modena, Italy

⁶Lymphoma unit, Department of Onco-hematology, IRCCS San Raffaele Scientific Institute, Milano, Italy

⁷Fondazione Italiana Linfomi, Modena, Italy

⁸Department of Molecular Biotechnologies and Health Sciences, Hematology Division, University of Torino, Turin, Italy

⁹Division of Hematology 1, AOU "Città della Salute e della Scienza di Torino", Torino, Italy

¹⁰Department of Hematology, Niguarda Cancer Center, Niguarda Hospital, Milan, Italy

¹¹Division of Hematology, Ospedale Oncologico Armando Businco, Cagliari, Italy

¹²Division of Hematology, Azienda Ospedaliero-Universitaria di Parma, Parma, Italy

¹³Department of Medicine, Section of Hematology, University of Verona, Verona, Italy

¹⁴Center of Hematology and Hemotherapy, Department of Internal Medicine, Faculty of Medicine, State University of Campinas, Campinas-SP, Brazil

¹⁵Department of Oncology, Division of Hematology, Azienda Ospedaliera Universitaria Senese & University of Siena, Italy

¹⁶Division of Medical Oncology A, National Cancer Institute, Aviano, Italy

¹⁷Department of Hematology, Azienda Ospedaliera Papardo, Messina, Italy

¹⁸Unit of Hematology, Stem Cell Transplantation, Transfusion Medicine and Cellular Therapy, University "Campus Bio-Medico", Rome, Italy

¹⁹Department of Cellular Biotechnology & Hematology, University "La Sapienza" - Rome

²⁰Division of Hematology 2, AOU "Città della Salute e della Scienza di Torino", Torino, Italy

²¹Department of Molecular Medicine, University of Pavia, Pavia Italy

Corresponding authors

Stefano Luminari

Programma di Ricerca Clinica Oncoematologica

Ematologia; Azienda Unità Sanitaria Locale, IRCCS, Reggio Emilia

Università di Modena e Reggio Emilia

viale Risorgimento 80,

42123 Reggio Emilia- Italy

tel:+39 0522 296119

email: stefano.luminari@unimore.it

Luca Arcaini

Divisione di Ematologia, Fondazione IRCCS Policlinico San Matteo

Viale Golgi 19 - 27100 Pavia, Italy

Tel +39 382 501308

Email: luca.arcaini@unipv.it

Short title

Early progression in marginal zone lymphomas

Key words

Marginal zone lymphoma, Splenic Marginal zone lymphoma, Extranodal marginal zone lymphoma, nodal marginal zone lymphoma, early progression, prognostic factors, Overall survival

Presented in abstract form at the 60th annual meeting of the American Society of

Hematology, San Diego, CA, 7 December 2018

Key points

- Patients with Marginal zone lymphoma (MZL) who experience progressive disease within 24 months from initial systemic therapy (POD24) have a significant increase of the risk of Death.
- Association of POD24 with survival is confirmed for the main MZL subtypes

- **Abstract**

Marginal zone Lymphomas (MZL) are indolent B cell non Hodgkin Lymphoma (INFL) and have a heterogeneous clinical behavior. Recently time to progression shorter than 24 months (POD24) was identified to stratify overall survival (OS) in follicular NHL and in INFL. Here we examined the ability of POD24 to predict subsequent OS in a large, international cohort of MZL as part of the NF10 prospective international registry (NCT02904577) headed by Fondazione Italiana Linfomi (FIL). POD24 was calculated only for MZL patients requiring immediate therapy and was defined as experiencing lymphoma progression within 24 months from diagnosis. Among the 1,325 patients enrolled in the NF10 study we identified 321 pts with MZL for whom immediate therapy was planned right after lymphoma diagnosis. Overall POD24 was confirmed in 59 patients (18%). Three-year OS for patients with POD24 was 53% with a HR of 19.5 (95%CI 8.4-45) compared with patients without POD24 (3 yr OS 95%). Association of POD24 with OS was confirmed for the subgroup of splenic and extranodal MZL.

Assessment of POD24 stratifies subsequent outcome in MZL and identifies high risk population.

Introduction

Marginal zone Lymphomas (MZLs) originate from mature B lymphocytes, and include splenic, nodal and extranodal subtypes (SMZL, NMZL, ENMZL)¹. Despite their indolent course a high heterogeneity of clinical behavior exists that warrants accurate tools to estimate the risk of relapse, progression or death in the individual patient. A prognostic index to foresee the outcome of all patients with MZL is missing but subtypes specific indexes have been proposed and validated for ENMZL² and for SMZL^{3,4}. Recently the analysis of progression free survival (PFS) has been used to identify surrogate endpoints in B-cell NHLs, with Progression of Disease at 24 months (POD24) identified to stratify overall survival (OS) in follicular NHL.⁵ Association of POD24 with OS has been confirmed in FL, Mantle Cell Lymphomas, Diffuse Large B-Cell and in peripheral T-cell Lymphoma and recently also in Indolent non follicular B-cell lymphomas (INFL).⁶⁻⁹

The NF10 Project was started in 2010 as a prospective observational study specifically conceived to investigate the outcome of INFL. We examined the ability of POD24 to predict subsequent OS in the large MZL cohort of patients enrolled in the NF10 study.

Methods:

Consecutive adult patients with newly diagnosed, histologic confirmed diagnosis of INFL were eligible for the NF10 study without any exclusion criteria and including SMZL, ENMZL, NMZL, lymphoplasmacytic lymphoma (LPL), Small Lymphocytic Lymphoma (SLL), and CD5-negative low-grade B cell lymphoma. Histologic diagnosis was required on tissue or on bone marrow biopsy and was based on local assessment. Patients were managed based on local institutional guidelines; treatment was left to physician discretion and was analyzed according to an intent to treat principle;. Watch and wait (WW) was defined as the decision not to treat

patients and by the absence of treatment within the first 3 months from the date of diagnosis. The definition of systemic therapy was applied to the use of systemic chemotherapy and of anti-CD20 monoclonal antibody alone or in combination with one or more chemotherapy agent; the use of antibiotics, radiotherapy or splenectomy were not considered as systemic therapies. The main aim of the current study was to validate the prognostic role of time to progression on the subgroup of patients with MZL who received immediate systemic therapy.

The main endpoint of this study was Overall Survival (OS); secondary endpoints were PFS and cause specific survival (CSS)¹⁰. POD24 was defined as experiencing lymphoma progression within 24 months from diagnosis. Survival analysis according to POD24 was calculated only for patients with events within 24 months (early progressors) or for those with at least 24 months of follow-up in case no POD24 defining event was reported (not early progressor). The OS was calculated from risk-defining event for early progressors; for patients without early progression OS was computed starting at 24 months from diagnosis, to reduce the effect of early progressive disease patients. Patients censored or died before 24 months were excluded from analysis. The study was approved by local ethic committees at any active center and signed consent form was mandatory for all enrolled patients.

Results and discussion

Between July 2010 and July 2018, 1,325 INFL cases have been registered in the NF10 study by 65 centers in Europe and South America. Demographic and clinical characteristics are summarized in table 1. Overall, 321 patients who received immediate systemic therapy and who had an adequate follow-up were identified as the main study population. The median follow-up was 43 months (range 1-92). Five-year PFS was 64% (95% CI 56 to 71%). Salvage

treatment of patients with progressive disease was immunochemotherapy in 46 cases (55%), radiotherapy in 6 (7%), observation in 7(8%). High dose therapy followed by autologous stem cell transplant (ASCT) was reported in 3 cases and in 23 cases it was not possible to obtain details on salvage therapy (27%). Overall 31 patients died; progressive disease was reported as the cause of death in 19/31 cases (61%). Five-year OS was 88% (95% CI 83 to 92%).

POD24 was reported in 59/321 patients (18%). Three-year OS for patients with POD24 was 53% (95%CI 37-67%) with a HR of 19.5 (95%CI 8.4 – 45.4) when compared to patients without POD24 (88%%, 95%CI 89-98%) (Figure1). Association of POD24 with OS was also confirmed with a lower HR, for patients who were not immediately treated (POD24 rate 25%, HR for OS 2.69 CI95% 1.04 to 6.92). The association of POD24 with OS was confirmed in ENMZL, SMZL and Diss-MZL subgroups (Figure 1). Our data confirm the strong association of time to progression with OS as seen for FL and, more recently, in a study of INFL by the University of Iowa/Mayo Clinic⁹. Differently from the US series our study was focused on a homogeneous population of MZL patients prospectively recruited in an international study who were treated with systemic chemo and/or immunotherapy. Notwithstanding small differences between the two studies and the use of two slightly different endpoints, both support the strong association of time to progression with the risk of death.

Recent data on FL suggest that early events could be enriched with transformed cases with more aggressive behavior.¹¹ In our study 66% of deaths for POD24 patients were referred to lymphoma progression and higher mortality of early relapsed was confirmed also by CSS analysis; moreover among the 90 patients who experienced progressive disease we were able to identify 7 patients with histologically transformed MZL all of whom were counted as POD24 cases. Thus also if the rate of transformation in our series was low compared to other

reported series^{12,13}, our report suggests that histological transformation (HT) might play a role in defining the quality of early events.

Another issue with POD24 patients is about salvage treatment. In follicular lymphomas, two recent reports suggested that the use of ASCT might be a better option compared to conventional salvage therapies for early relapser^{14,15}. In MZL the efficacy of ASCT is controversial and its role as salvage therapy for POD24 patients remains an open research question. Indeed, very few POD24 patients were treated with ASCT in our study.

The finding of early progression (POD24) as strong marker of poor outcome is useful but its clinical utility to support initial treatment choice is limited. Logistic univariate analysis adjusted by treatment modality (immunochemotherapy vs chemotherapy without rituximab) identified clinical and laboratory parameters associated with higher risk of POD24 (age >60, performance status, systemic symptoms, bone marrow involvement, low serum albumin, elevated LDH, Beta2Microglobulin, low Hemoglobin, reduced Platelet count, low Absolute lymphocyte count). Among tested prognostic scores FLIPI predicted the risk of POD24 (12% and 27% for 0-2 and 3-5 risk factors; $p=0.001$). Future research efforts should focus on the identification of these high risk patients at the time of diagnosis, in order to enable personalized therapy.

In conclusion assessment of POD24 predicts subsequent outcome in MZL in need of therapy and its association with OS is confirmed for the main MZL subtypes. Our data have important implications for the management of patients with MZL and for a better understanding of the disease.

ACKNOWLEDGMENTS

Author thanks dr. Jacqueline Costa for support in manuscript preparation and language revision.

AUTHOR CONTRIBUTIONS

SL and LA designed research, analyzed an interpreted data. LM performed statistical analysis, analyzed an interpreted data. All authors performed research, collected data, wrote and approved manuscript

CONFLICT OF INTEREST DISCLOSURES

SL holds a consultancy/advisory role from Roche, Celgene, Sandoz, Gilead and Teva. FC holds advisory role from Takeda and Janssen Cilag. MV holds advisory role from Janssen Cilag and Roche; travel expenses from Janssen Cilag, Abbvie and Gilead. FM holds an advisory role from Roche, Celgene and Sandoz; honoraria from Roche, Gilead, Mundipharma, Janssen and Takeda; travel expenses from Takeda and Celgene; research funding from Roche. DM holds advisory role from Janssen Cilag and Abbvie. OA hold advisory role from Celgene, Takeda, Janssen Cilag, Roche, Servier and Amgen; sponsorships from Gilead, Janssen Cilag, Servier, Celgene Takeda and Amgen. LA reports consulting or advisory roles for Bayer, Celgene, Gilead Sciences, Roche, Sandoz, Janssen–Cilag, VERASTEM and research funding from Gilead Sciences and participation in a speakers bureau for Celgene.

All other authors have nothing to declare.

References

1. Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. *Blood*. 2016;127(20):2375-2390. doi:10.1182/blood-2016-01-643569
2. Thieblemont C, Cascione L, Conconi A, et al. A MALT lymphoma prognostic index. *Blood*. 2017;130(12):1409-1417. doi:10.1182/blood-2017-03-771915
3. Arcaini L, Rattotti S, Gotti M, Luminari S. Prognostic assessment in patients with indolent B-cell lymphomas. *Sci World J*. 2012;2012. doi:10.1100/2012/107892
4. Montalbán C, Abaira V, Arcaini L, et al. Risk stratification for Splenic Marginal Zone Lymphoma based on haemoglobin concentration, platelet count, high lactate dehydrogenase level and extrahilar lymphadenopathy: Development and validation on 593 cases. *Br J Haematol*. 2012;159(2):164-171. doi:10.1111/bjh.12011
5. Casulo C, Byrtek M, Dawson KL, et al. Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: An analysis from the National LymphoCare Study. *J Clin Oncol*. 2015;33(23):2516-2522. doi:10.1200/JCO.2014.59.7534
6. Maurer MJ, Ellin F, Srouf L, et al. International assessment of event-free survival at 24 months and subsequent survival in peripheral T-cell lymphoma. In: *Journal of Clinical Oncology*. ; 2017. doi:10.1200/JCO.2017.73.8195
7. Maurer MJ, Ghesquières H, Jais JP, et al. Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy. *J Clin Oncol*. 2014. doi:10.1200/JCO.2013.51.5866
8. Visco C, Tisi MC, Evangelista A, et al. Time to progression of mantle cell lymphoma after high-dose cytarabine-based regimens defines patients risk for death. *British Journal of Haematology*. 2018.
9. Tracy SI, Larson MC, Feldman AL, et al. The utility of prognostic indices, early events, and histological subtypes on predicting outcomes in non-follicular indolent B-cell lymphomas. *Am J Hematol*. 2019. doi:10.1002/ajh.25473
10. Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of hodgkin and non-hodgkin lymphoma: The lugano classification. *J Clin Oncol*. 2014;32(27):3059-3067. doi:10.1200/JCO.2013.54.8800
11. Freeman CL, Savage KJ, Villa D, et al. Frontline Therapy with Bendamustine and Rituximab (BR) in Follicular Lymphoma: Prognosis Among Patients with Progression of Disease By 24 Months (POD24) Is Poor with Majority Having Transformed Lymphoma. *Blood*. 2018;132(Suppl 1):2873 LP - 2873. doi:10.1182/blood-2018-99-113675
12. Conconi A, Franceschetti S, Aprile von Hohenstaufen K, et al. Histologic transformation in marginal zone lymphomas. *Ann Oncol*. 2015;26(11):2329-2335. doi:10.1093/annonc/mdv368
13. Alderuccio JP, Zhao W, Desai A, et al. Risk Factors for Transformation to Higher-Grade Lymphoma and Its Impact on Survival in a Large Cohort of Patients With Marginal Zone Lymphoma From a Single Institution. *J Clin Oncol*. 2018;JCO.18.00138. doi:10.1200/JCO.18.00138
14. Casulo C, Friedberg JW, Ahn KW, et al. Autologous Transplantation in Follicular Lymphoma with Early Therapy Failure: A National LymphoCare Study and Center for International Blood and Marrow Transplant Research Analysis. *Biology of Blood and Marrow Transplantation*. 2018.
15. Jurinovic V, Metzner B, Pfreundschuh M, et al. Biology of Blood and Marrow Transplantation Autologous Stem Cell Transplantation for Patients with Early Progression of Follicular Lymphoma : A Follow-Up Study of 2 Randomized Trials from the German Low Grade Lymphoma Study Group. 2018;24:1172-1179. doi:10.1016/j.bbmt.2018.03.022

Table 1 - Characteristic of the 321 MZL patients we received immediate systemic therapy (study population) and comparison with MZL patients enrolled in the NF10 who did not receive immediate therapy.





<i>Factor</i>		<i>Missing</i>	<i>Untreated (%)</i>	<i>Treated (%)</i>	<i>P</i>
Total			286	321	
MZL(*)	ENMZL	-	96 (34)	146 (46)	<0.001
	SMZL	-	122(43)	84 (26)	
	NMZL	-	30 (10)	32 (10)	
	DissMZL	-	38 (13)	59 (18)	
Age	> 60 years	-	203 (71)	202 (62)	0.039
ECOG PS	>1	3	8 (3)	21 (7)	0.036
Symptoms	B	3	19 (7)	66 (21)	<0.001
Hb	< 12g/dl	3	73 (26)	129 (40)	<0.001
Platelets	< 150x10 ⁹ /ul	5	97 (34)	90 (28)	0.094
LDH	> UNL	30	61(23)	96 (31)	0.049
B2M	> UNL	17	96 (41)	156 (60)	<0.001
LN size	> 6cm	61	8 (3)	34 (11)	<0.001
Albumin	< 3.5 g/dl	74	15 (8)	51 (22)	<0.001
HBV serology	+	12	23 (8)	25 (9)	0.88
HCV serology	+	27	35 (12)	67 (21)	0.012
Treatment					
	Watch & wait	7	286(100)	-	
	Alk-Mono	-	-	16 (5)	
	R-Mono	-	-	30 (9)	
	R-Alkylating	-	-	83 (26)	
	R-CHOP	-	-	48 (15)	
	R-Bendamustine	-	-	112 (35)	
	R-Fludarabine	-	-	3 (1)	
	Other	-	-	21 (6)	

Legend to table: (*) Eligible patients were classified as SMZL, ENMZL and NMZL according to local pathologic diagnosis. Patients with histologic features consistent with MZL with concomitant involvement of the marrow and/or spleen and/or lymph nodes and/or extranodal sites but lacking the diagnostic features of splenic, nodal or extranodal MZL were categorized as disseminated MZL (dissMZL). MZL: Marginal Zone Lymphoma; ENMZL: Extranodal MZL; SMZL: Splenic MZL; NMZL: Nodal MZL; Diss MZL: Disseminated MZL; PS: Performance Status; Hb: Hemoglobin; LDH: Lactate dehydrogenase; B2M: beta2-microglobulin; LN: lymph node; HBV: Hepatitis B virus; HCV: Hepatitis C virus; Alk: alkylating agent; R: Rituximab

Figure legend:

Figure 1 Overall survival by POD24 and by marginal zone lymphoma subtypes

Overall survival from risk-defining event after diagnosis in patients with MZL who were immediately treated after diagnosis a) Patients with MZL: POD24 rate 18%; 3-yr OS POD24 achieve 95% vs fail 53%, $p < 0.001$ [HR 19.5; 95%CI 8.40-45.4], b) Patients with SMZL: POD rate 25%; 3-yr OS POD24 achieve 95% vs fail 44%, $p < 0.001$; c) Patients with diss-MZL: POD rate 20%; 3-yr OS POD24 achieve 93% vs fail 33%, $p < 0.001$; d) Patients with ENMZL: POD rate 16%; 3-yr OS POD24 achieve 98% vs fail 71%, $p < 0.001$. Association of POD24 with OS could not be assessed for nodal MZL patients because too few events have been reported in this subgroup to do any inference. Legend to figure: MZL, Marginal Zone Lymphoma; SMZL Splenic MZL; Diss MZL, Disseminated MZL; ENMZL, Extranodal MZL.



— POD24 Achieve - - - POD24 Fail



Prepublished online July 10, 2019;
doi:10.1182/blood.2019001088

Early Progression As a Predictor of Survival in Marginal Zone Lymphomas: An Analysis from the FIL-NF10 Study

Stefano Luminari, Michele Merli, Sara Rattotti, Vittoria Tarantino, Luigi Marcheselli, Federica Cavallo, Marzia Varettoni, Benedetta Bianchi, Francesco Merli, Alessandra Tedeschi, Giuseppina Cabras, Francesca Re, Carlo Visco, Marcia Torresan Delamain, Emanuele Cencini, Michele Spina, Simone Ferrero, Angela Ferrari, Marina Deodato, Donato Mannina, Ombretta Annibali, Angela Rago, Lorella Orsucci, Irene Defrancesco, Marco Frigeni, Marina Cesaretti and Luca Arcaini

Information about reproducing this article in parts or in its entirety may be found online at:
http://www.bloodjournal.org/site/misc/rights.xhtml#repub_requests

Information about ordering reprints may be found online at:
<http://www.bloodjournal.org/site/misc/rights.xhtml#reprints>

Information about subscriptions and ASH membership may be found online at:
<http://www.bloodjournal.org/site/subscriptions/index.xhtml>

Advance online articles have been peer reviewed and accepted for publication but have not yet appeared in the paper journal (edited, typeset versions may be posted when available prior to final publication). Advance online articles are citable and establish publication priority; they are indexed by PubMed from initial publication. Citations to Advance online articles must include digital object identifier (DOIs) and date of initial publication.